Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$321.90 USD

321.90
802,271

+0.11 (0.03%)

Updated Nov 7, 2024 03:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Amgen (AMGN) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Amgen (AMGN) closed at $322.67 in the latest trading session, marking a +1.12% move from the prior day.

AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why

by Zacks Equity Research

Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.

Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea

by Zacks Equity Research

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.

Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $335.61, denoting a -0.52% change from the preceding trading day.

Ahan Chakraborty headshot

NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?

by Ahan Chakraborty

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

Amgen (AMGN) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Amgen (AMGN) reachead $332.80 at the closing of the latest trading day, reflecting a -0.73% change compared to its last close.

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen (AMGN) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Amgen (AMGN) closed the most recent trading day at $335.26, moving +0.85% from the previous trading session.

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

by Zacks Equity Research

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

Why Amgen (AMGN) Outpaced the Stock Market Today

by Zacks Equity Research

Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

by Zacks Equity Research

TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?

by Kinjel Shah

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.

Why the Market Dipped But Amgen (AMGN) Gained Today

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $330.64, denoting a +0.04% change from the preceding trading day.

Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound

by Zacks Equity Research

LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.

Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday

by Zacks Equity Research

VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.

Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWV

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk

by Zacks Equity Research

Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Sundeep Ganoria headshot

Medicare Releases Negotiated Prices on 10 Expensive Drugs

by Sundeep Ganoria

Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.

Kinjel Shah headshot

Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?

by Kinjel Shah

Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.

Ahan Chakraborty headshot

Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss

by Ahan Chakraborty

Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.